NCT07102979View on ClinicalTrials.gov

Remedial Mechanism of Simvastatin and Ursodeoxycholic Acid in Liver Cirrhosis: Crosstalk of Bile Secretion, Gut Microbiome, and Host Immune Response

NAEnrolling by invitationINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Liver Cirrhosis
Interventions
DRUG

Ursodeoxycholic Acid (URSO)

Ursodeoxycholic acid (UDCA) was administered orally at a dose of 10 mg/kg/day for 6 months.

DRUG

Simvastatin

Simvastatin was administered orally at a dose of 40 mg/day for 6 months.

Trial Locations (1)

833

Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City

All Listed Sponsors
lead

Chang Gung Memorial Hospital

OTHER